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CC BY-NC-ND license (http://creativeBackground: Calcineurin inhibitors (CNIs) exhibit remarkable efficacy in atopic dermatitis
(AD). Tacrolimus, one type of CNI, is prevalently used to treat AD. AD is a chronic inflammatory
disease that exhibits predominant infiltration of T-helper type 2 (Th2) cell in the acute phase
and a mixed Th1 and Th0 cell pattern in chronic lesions. Cytokines such as tumor necrosis fac-
tor-a (TNF-a), Th2-related chemokines [e.g., macrophage-derived chemokine (MDC)/CCL22
and I-309/CCL1], Th1-related chemokines [e.g., interferon g-induced protein 10 (IP-10)/
CXCL10], and neutrophil chemoattractant growth-related oncogene-a (GRO-a)/CXCL1 are
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410 K.-T. Chang et al.of AD-associated cytokines and chemokines remains unknown. The intracellular mechanisms of
tacrolimus are also unclear.
Methods: Human monocytic cell line THP-1 cells were pretreated with tacrolimus and stimu-
lated with lipopolysaccharide (LPS). The MDC, I-309, IP-10, GRO-a, and TNF-a concentrations
of the cell supernatants were measured using enzyme-linked immunosorbent assay. Intracel-
lular signaling was investigated using the Western blot analysis.
Results: Tacrolimus suppressed the expression of MDC, IP-10, I-309, GRO-a, and TNF-a in LPS-
stimulated THP-1 cells in a dose- and time-dependent manner. All three mitogen-activated
protein kinase (MAPK) inhibitors and the nuclear factor-kB inhibitor suppressed LPS-induced
MDC, I-309, and TNF-a expressions in THP-1 cells. Only MAPK inhibitors suppressed LPS-
induced expression of IP-10 and GRO-a. Tacrolimus suppressed the LPS-induced phosphoryla-
tion of MAPK-extracellular signal-related kinase (ERK).
Conclusion: Tacrolimus suppressed LPS-induced MDC, I-309, IP-10, GRO-a, and TNF-a expres-
sions in monocytes through the MAPK-ERK pathway; thus, tacrolimus may yield therapeutic ef-
ficacy by modulating AD-associated cytokines and chemokines.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Atopic dermatitis (AD) is a chronic inflammatory disease in
children. It is highly pruritic and frequently seen in infants
and children, particularly among patients with atopy. The
pathophysiology of AD is complex, including skin barrier
dysfunction,1 immune responses to allergens, the impair-
ment of antimicrobial defense, and interactions among
susceptible genes and the environment.2 The amplification
cycle of atopic skin inflammation contributes to the dis-
ease.3 Patient scratching induces mechanical trauma,
resulting in the production of proinflammatory cytokines
such as interleukin-1a (IL-1a), IL-1b, tumor necrosis factor-
a (TNF-a), and granulocyte-macrophage colony-stimulating
factor (GM-CSF). Subsequently, the chemoattractants and
adhesion molecules are upregulated, directing the
recruitment of leukocytes toward the skin lesions.4 Both T-
helper cell type 2 (Th2)-related and T-helper cell type 1
(Th1)-related cytokines contribute to the biphasic inflam-
matory phase in AD, including an initial Th2-dominant
phase preceding a chronic Th0- and Th1-dominant phase.5
Compared with the skin and blood of healthy patients, AD
patients exhibit increased expression of Th2-cytokines IL-4,
IL-5, IL-13, and decreased expression of Th1-cytokine
interferon-g (IFN-g) in skin lesions and peripheral blood
during the acute stage of the disease.2 Chronic lichenified
AD skin lesions have fewer IL-4 and IL-13 expressions but
significantly greater IL-5, GM-CSF, IL-12, and IFN-g expres-
sions than acute AD skin lesions.6 IL-12 switches initial Th2
immune responses to Th1 immune responses in the trans-
formation from the acute to the chronic phase of AD.2,6,7
Tissue damages among AD lesions might release neutro-
phil chemoattractants. The expression of neutrophil che-
moattractants contributes to the recruitment, activation,
and proliferation of neutrophils among AD lesions.8
The migration of the inflammatory cells is regulated by
the interaction of chemokines and chemokine receptors.9
AD patients have a high percentage of CD4þ T lymphocyte
bearing CCR4 receptors, which can bind to Th2-related
chemokines macrophage-derived chemokine (MDC) and
thymus and activation-regulated chemokine (TARC).10Subsequently, these CCR4-containing Th2 lymphocytes are
attracted to the AD lesions.11 In patients diagnosed with
AD, the serum levels of TARC and MDC are increased and
positively correlated with severity.12 In addition, I-309/
CCL1 is a Th2-related chemokine. I-309 is increased in AD
patients, particularly during the acute phase and can be a
useful marker for distinguishing AD from psoriasis.13 IFN-g-
induced protein 10 (IP-10)/CXCL10 is a Th1 cell-related
chemokine and its production can be stimulated by the
IFN-g produced in Th1 cells. IP-10 consequently attracts
and recruits additional activated lymphocytes.14 The
chemotactic action of IP-10 plays a role in both innate and
adaptive immunity.15 Growth-related oncogene-a (GRO-a)/
CXCL1 is a powerful neutrophil chemoattractant, which
also plays a crucial role in chronic inflammation and several
autoimmune diseases.16 TNF-a is a proinflammatory cyto-
kine and is considered a potential biomarker of AD.17 TNF-a
levels rapidly increase after mechanical trauma and skin
barrier disruption, inducing the production of chemo-
attractants and adhesion molecules, and subsequently
facilitating the recruitment and proliferation of leukocytes
in the skin.4
Calcineurin inhibitors (CNIs), such as tacrolimus, are
widely used as topical agents to treat AD by modulating T-
cell activity. Tacrolimus inhibits the phosphatase activity of
calcineurin, blocks nuclear translocation of the transcrip-
tion factor-nuclear factor of activated T cells (NFAT), and
inhibits the production of cytokines.18
According to the results of pharmacokinetic studies, the
systemic exposure to tacrolimus after ointment application
was low and highly variable. When the size of the body
surface area treated by tacrolimus increased, the systemic
exposure to tacrolimus increased proportionally.19,20 In the
study on a group of young children treated with topical
0.03% tacrolimus two times daily for 2 years, Mandelin
et al21 found that the concentration of tacrolimus was less
than 1.0 ng/mL in 98% of blood samples. Topically applied
tacrolimus has the highest absorption in the initial stage of
AD when the skin barrier is extremely impaired. When the
disease improves and epidermal barrier recovers, pene-
tration of tacrolimus into the skin decreases.22 Significant
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in diseases with profound skin barrier damage (e.g., Neth-
erton syndrome, lamellar ichthyosis, pyoderma gan-
grenosum). In patients with severe skin barrier dysfunction,
the serum levels of tacrolimus after topical application
could reach 20e40 ng/mL.23
T-cell subpopulations, mast cells, and eosinophils
participate in the immunological mechanisms of AD.24
Monocytes also contribute to the initiation and progres-
sion of this disease. The high-affinity receptor for immu-
noglobulin E (FcεRI) is upregulated in atopic monocytes in
patients with AD. The FcεRI-bearing monocytes may be
recruited into the dermis by chemotactic signals. They
differentiate into macrophages, tissue-specific dendritic
cells such as Langerhans cells (LCs), and inflammatory
dendritic epidermal cells (IDECs).25,26 Macrophages, LCs,
and IDECs present antigens to T cells and initiate T-cell-
mediated immune responses.27 Besides, monocytes from
most AD patients show a hyperactivated status.28 They are
activated through the recognition of microbial molecules by
Toll-like receptors (TLRs), and subsequently produce large
amounts of proinflammatory cytokines. The well-known
microbial ligands are peptidoglycan and lipoteichoic acid
for TLR2, and lipopolysaccharide (LPS) for TLR4.29
The suppressive effect of tacrolimus on the expression
of cytokines in T cells has been widely studied. However,
whether tacrolimus modulates the expression of Th1- and
Th2-related chemokines, neutrophil chemoattractant, and
TNF-a in monocytes remains unknown. In this study, we
investigated the modulatory effects of tacrolimus on TNF-
a, Th1- and Th2-related chemokines, and neutrophil che-
moattractant expressions in monocytes. In addition, we
explored the detailed mechanisms about the effects of
tacrolimus on the expressions of these LPS-induced cyto-
kines and chemokines in monocytes.
Materials and methods
Cell preparation
The human monocytic cell line THP-1 cells (American Type
Culture Collection, Rockville, MD, USA) were cultured in
Roswell Park Memorial Institute-1640 medium (Sigma
Chemical Co., St. Louis, MO, USA) supplemented with 10%
fetal bovine serum, 100 U/mL of penicillin, and 100 mg/mL
of streptomycin at 37C, and 5% CO2 in a humidified incu-
bator. The cells were centrifuged at 1500 rpm for 5 minutes
and resuspended in fresh medium in 24-well plates at a
concentration of 106/mL for 24 hours prior to experimental
use. The cells were pretreated with tacrolimus (Sigma
Chemical Co.) at various concentrations (0.5 ng/mL, 5 ng/
mL, and 50 ng/mL) for 2 hours before LPS stimulation
(0.2 mg/mL; Escherichia coli; Sigma Chemical Co.). The cell
supernatants were collected 24 hours and 48 hours after
LPS stimulation.
Cell viability assay
The cytotoxic effects of tacrolimus on THP-1 cells at
various concentrations (0.5 ng/mL, 5 ng/mL, and 50 ng/mL)
were investigated using the WST-1 Cell Viability andProliferation Assay Kit (Roche Applied Science, Mannheim,
Germany) according to the manufacturer’s instructions.
Enzyme-linked immunosorbent assay
The MDC, I-309, IP-10, GRO-a, and TNF-a levels of the cell
supernatants were determined using commercially avail-
able enzyme-linked immunosorbent assay-based assay sys-
tems (R&D Systems, Minneapolis, MN, USA) according to the
protocols recommended by the manufacturer. The samples
were examined with a Dynatech MRX plate reader at
450 nm and 540 nm using Revelation software (Dynatech
Laboratories Ltd., Chantilly, VA, USA).
Western blotting and c-Jun mitogen-activated
protein kinase activity assay
After pretreatment with or without tacrolimus (5 ng/mL
and 50 ng/mL) for 2 hours, the cells were stimulated using
LPS (0.2 mg/mL) for 1 hour and were lysed with equal vol-
umes of ice-cold lysis buffer. After centrifuging at 13,000g
for 15 minutes, cell lysates were used to determine the
protein concentration using a BCA Protein Assay Reagent Kit
(Thermo Fisher Scientific, Waltham, MA, USA); the con-
centration of each sample was equalized using a lysis
buffer. Equal amounts of cell lysates were analyzed using
Western blot with anti-mitogen-activated protein kinase
[anti-MAPKs; p38, extracellular signal-related kinase (ERK),
and c-Jun N-terminal kinase (JNK)], anti-phospho-MAPK
(phospho-p38, phospho-ERK, and phospho-JNK), anti-p65k,
and anti-phospho-p65 antibodies (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA). The immunoreactive bands
were visualized using a horseradish peroxidase-conjugated
secondary antibody and an enhanced chemiluminescence
system (Amersham Pharmacia Biotech, Piscataway, NJ,
USA).
Statistical analyses
All data are presented as mean  standard deviation. The
variations between the experimental and control groups
were analyzed using the ManneWhitney U test. A p value
<0.05 was considered indicative of significant between-
group variations.
Results
Tacrolimus suppressed LPS-induced MDC and I-309
expressions in THP-1 cells
We investigated how tacrolimus affected the expression of
Th2-related chemokines. Fig. 1 indicates that the LPS-
induced MDC expression in THP-1 cells was inhibited by
tacrolimus in a time- and dose-dependent manner
(0.5e50 ng/mL after 24 hours and 48 hours of LPS stimu-
lation; Fig. 1A and B). Tacrolimus alone did not affect MDC
expression. Similarly, the LPS-induced I-309 expression in
THP-1 cells was also inhibited by tacrolimus in a time- and
dose-dependent manner (0.5 ng/mL after 48 hours of LPS
stimulation; 5e50 ng/mL after 24 hours and 48 hours of LPS
Figure 1. Tacrolimus suppressed lipopolysaccharide (LPS)-induced Th2-related chemokines expression in human monocytes.
Tacrolimus suppressed macrophage-derived chemokine (MDC) expression in THP-1 cells after (A) 24 hours and (B) 48 hours of LPS
stimulation. Results presented are the mean  SD of independent experiments. *p < 0.01 and **p < 0.005 between groups of LPS
treatment with and without tacrolimus pretreatment. Tacrolimus suppressed LPS-induced I-309 expression in THP-1 cells after (C)
24 hours and (D) 48 hours of LPS stimulation. Results presented are the mean  SD of independent experiments. *p < 0.01 and
**p < 0.005 between groups treated with LPS with and without tacrolimus pretreatment. SD Z standard deviation.
412 K.-T. Chang et al.stimulation; Fig. 1C and D). Tacrolimus alone did not affect
I-309 expression.
Tacrolimus suppressed LPS-induced IP-10
expression in THP-1 cells
We subsequently investigated how tacrolimus affected the
Th1-related chemokine, IP-10. Tacrolimus (5e50 ng/mL)
suppressed LPS-induced IP-10 expression in THP-1 cellsFigure 2. Tacrolimus suppressed lipopolysaccharide (LPS)-indu
Tacrolimus suppressed interferon g-induced protein 10 (IP-10) prod
stimulation. Results presented are the mean  standard deviation o
groups treated with LPS with and without tacrolimus pretreatmenafter 24 hours and 48 hours of LPS stimulation. Tacrolimus
alone did not affect IP-10 expression (Fig. 2A and B).
Tacrolimus suppressed LPS-induced GRO-a
expression in THP-1 cells
We also investigated how tacrolimus affected the chemo-
attractant GRO-a expression. Tacrolimus (5e50 ng/mL)
suppressed the LPS-induced GRO-a expression in THP-1ced Th1-related chemokine expression in human monocytes.
uction in THP-1 cells after (A) 24 hours and (B) 48 hours of LPS
f independent experiments. *p < 0.01 and **p < 0.005 between
t.
Figure 3. Tacrolimus suppressed lipopolysaccharide (LPS)-induced neutrophil chemoattractant expression in human monocytes.
Tacrolimus suppressed growth-related oncogene-a (GRO-a) expression in THP-1 cells after (A) 24 hours and (B) 48 hours of LPS
stimulation. Results presented are the mean  standard deviation of independent experiments. *p < 0.05 and **p < 0.005 between
groups treated with LPS with and without tacrolimus pretreatment.
Tacrolimus suppresses AD-associated cytokines 413cells after 24 hours and 48 hours of LPS stimulation (Fig. 3A
and B). Tacrolimus alone did not affect the GRO-a
expression.
Tacrolimus suppressed LPS-induced TNF-a
expression in THP-1 cells
We subsequently investigated how tacrolimus affects the
LPS-induced TNF-a production in THP-1 cells. Fig. 4 shows
that LPS-induced TNF-a expression in THP-1 cells was
inhibited by tacrolimus (0.5 ng/mL after 48 hours of stim-
ulation; 5e50 ng/mL after 24 hours and 48 hours of stimu-
lation). Tacrolimus alone did not affect the TNF-a
expression (Fig. 4A and B).
Tacrolimus exhibited no cytotoxic effect on THP-1
cells
Because tacrolimus exerted suppressive effects on MDC, I-
309, IP-10, GRO-a, and TNF-a, we investigated whether the
suppressive effect of tacrolimus on the expression of che-
mokines and cytokines resulted from its cytotoxic effect onFigure 4. Tacrolimus suppressed lipopolysaccharide (LPS)-induc
Tacrolimus suppressed LPS-induced tumor necrosis factor-a (TNF-a)
LPS stimulation, tacrolimus suppressed TNF-a expression in a dose-d
deviation of independent experiments. *p < 0.05, **p < 0.01, and *
tacrolimus pretreatment.THP-1 cells. A cell viability test indicated that tacrolimus
exerted no cytotoxic effect on THP-1 cells (Fig. 5).
Tacrolimus suppressed LPS-induced
phosphorylated ERK expression in THP-1 cells
The stimulation of TLRs activates MyD88-dependent path-
ways, including nuclear factor-kB (NF-kB) transcription
factors, and the MAPKs ERK, p38, and JNK pathways.30 We
previously reported that the LPS-induced MDC,31 I309,31,32
IP-10,32,33 GRO-a,34 and TNF-a35 expressions in monocytes
involved the MAPK and NF-kB pathways. We then investi-
gated whether tacrolimus suppressed LPS-induced MDC,
I309, IP-10, GRO-a, and TNF-a expressions through the
MAPK and NF-kB pathways. We observed that tacrolimus
(5 ng/mL and 50 ng/mL) suppressed the LPS-induced
phosphorylation of MAPK-ERK (Fig. 6A), but not that of
MAPK-p38 (Fig. 6B) or JNK (Fig. 6C), and exerted no effect
on the LPS-induced phosphorylation of NF-kB-p65 (Fig. 6D)
in THP-1 cells. Densitometry analysis results are shown
below each Western blot data. Therefore, tacrolimus may
suppress LPS-induced MDC, I309, IP-10, GRO-a, and TNF-a
expressions through the MAPK-ERK pathway.ed proinflammatory cytokine expression in human monocytes.
production in monocytes. After (A) 24 hours and (B) 48 hours of
ependent manner. Results presented are the mean  standard
**p < 0.005 between groups treated with LPS with and without
Figure 5. Tacrolimus had no cytotoxic effect on human
monocytes. The treatment with tacrolimus at the concentra-
tion of 0.5 ng/mL, 5 ng/mL, and 50 ng/mL did not affect the
cell viability in THP-1 cells.
Figure 6. Tacrolimus modulates the MAPK pathway in human
induced phosphorylation of (A) MAPK-ERK but not (B) MAPK-p38,
phosphorylation of (D) NF-lB-p65 expression in THP-1 cells. Dens
Results presented are the mean  standard deviation of three i
experiment representative of three is shown. *p  0.05 compared w
JNK Z c-Jun N-terminal kinase; MAPK Z mitogen-activated protei
414 K.-T. Chang et al.Discussion
Recent clinical studies have demonstrated that topical CNIs,
such as tacrolimus and pimecrolimus, were alternative drugs
for treating moderate to severe AD that is unresponsive to
first-linemedicines. Themechanismof tacrolimus in treating
AD involves inhibiting the activation of T lymphocytes and
their derived Th2-related cytokines (IL-3, IL-4, IL-5, and IL-
13) and Th1-related cytokines (IFN-g, IL-12, IL-11, IL-18, GM-
CSF, and TGF-b).36 Tacrolimus binds to the FK506-binding
protein and the complex inhibits calcineurin phosphatase
and T-lymphocytes activation. Tacrolimus also down-
regulates the synthesis of inflammatory cytokines, such as
TNF-a, IL-1b, and IL-6, by Tcells.37 Recent evidence suggests
that chemokines are involved in AD. Higher amounts of Th2-
related chemokines, TARC and MDC, are present in the
plasma of AD patients, and their levels are positively corre-
lated with disease severity.38,39 The expression of I-309 is
significantly high in the acute lesional skin of AD patients.40
Th1-related chemokine IP-10 executes a powerfulmonocytes. Tacrolimus suppressed lipopolysaccharide (LPS)-
or (C) MAPK-JNK. Tacrolimus had no effect on LPS-induced
itometry analysis results are shown below each Western blot.
ndependent experiments. For Western blotting analyses, one
ith LPS-treated cells. ERKZ extracellular signal-related kinase;
n kinase; NF-lB Z nuclear factor lB.
Tacrolimus suppresses AD-associated cytokines 415chemotactic action on activated lymphocytes toward in-
flammatory sites, particularly during infection.15 The che-
moattractant GRO-a can trigger neutrophil and T-
lymphocyte chemotaxis, particularly after tissue damage.16
TNF-a, as a proinflammatory cytokine, plays a key role in the
inflammation of AD.17 In this study, we showed for the first
time in the literature that tacrolimus can affect the function
of monocytes by suppressing the expression of cytokines and
chemokines. These findings suggest that in addition to
inhibiting the activation of T cells, tacrolimus may exert
therapeutic effects on AD by modulating the expression of
AD-related cytokines and chemokines in monocytes.
Chemokines are crucial for the attraction and activation
of various types of leukocytes and are also involved in the
inflammatory processes of various acute and chronic in-
flammatory diseases. For example, the expression of Th2-
related chemokine, MDC, is increased in the exhaled breath
condensate and serum of asthmatic patients.41 The expres-
sion of Th1-related chemokine, IP-10, is also increased in the
airways of asthmatic patients.42 TNF-a mediates the acute
phase reaction of inflammation by activating T lymphocytes
and recruiting additional inflammatory cells into target tis-
sues during inflammatory diseases and the post-
transplantation rejection effect. Medicines, such as tacro-
limus, that modulate the expression of chemokines and cy-
tokines can potentially treat inflammatory diseases.
Several studies have shown that tacrolimus not only in-
hibits NFAT activation by blocking calcineurin, but also af-
fects the activation of MAPK-signaling pathways by
suppressing the phosphorylation of MAPK-p38 and JNK in
primary human T lymphocytes.43 Similarly, in this study, we
determined that tacrolimus inhibited the activation of the
MAPK pathway by suppressing the LPS-induced phosphory-
lation of MAPK-ERK, but not that of MAPK-p38/JNK, and also
did not have any effect on the phosphorylation of NF-kB-
p65. Based on these findings and our previous reports,31e35
tacrolimus may interfere with the MAPK-ERK pathway in
monocytes to modulate the expression of chemokines and
cytokines. The suppressive effect of tacrolimus in MAPK-
ERK may indicate its potential to inhibit other MAPK-
related inflammatory processes.44
In conclusion, in this study,wedetermined that tacrolimus
suppressed the expression of AD-related chemokines and
TNF-a in monocytes. According to our review of relevant
research, this study is the first to suggest that tacrolimus
exerts therapeutic effects by modulating the expression of
AD-related chemokines and TNF-a. We also determined that
this effect was achieved by suppressing the MAPK-ERK
pathway. By inhibiting the expression of chemokines and
TNF-a in monocytes, tacrolimus may exhibit therapeutic
potential in treating other inflammatory disorders.Conflicts of interest
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